| Natera, Inc. |
Director |
Common Stock |
1,550,280 |
$219,225,094 |
$141.41 |
25 Apr 2025 |
by Sofinnova Venture Partners IX, L.P. |
| BioAge Labs, Inc. |
Director |
Common Stock |
2,227,124 |
$40,088,232 |
$18.00 |
27 Sep 2024 |
Sofinnova Venture Partners XI, L.P. |
| Rapport Therapeutics, Inc. |
Director |
Common Stock |
1,863,327 |
$18,596,003 |
$9.98 |
01 Jul 2024 |
By Sofinnova Venture Partners XI, L.P. |
| Natera, Inc. |
Director |
Common Stock |
46,260 |
$6,541,626 |
$141.41 |
25 Apr 2025 |
Direct |
| ArriVent Biopharma, Inc. |
Director |
Common Stock |
1,696,752 |
$6,193,145 |
$3.65 |
30 Jan 2024 |
Sofinnova Venture Partners XI, L.P. |
| BioAge Labs, Inc. |
Director |
Common Stock |
26,497 |
$476,946 |
$18.00 |
27 Sep 2024 |
CRESTLINE SUMMIT PINNACLE MASTER, L.P. |
| Rapport Therapeutics, Inc. |
Director |
Common Stock |
40,851 |
$407,693 |
$9.98 |
01 Jul 2024 |
By Crestline Summit Master, SPC - PEAK SP |
| Rapport Therapeutics, Inc. |
Director |
Common Stock |
39,661 |
$395,817 |
$9.98 |
01 Jul 2024 |
By CRESTLINE SUMMIT PINNACLE MASTER, L.P. |
| BioAge Labs, Inc. |
Director |
Common Stock |
21,814 |
$392,652 |
$18.00 |
27 Sep 2024 |
Crestline Summit Master, SPC - PEAK SP |
| Rapport Therapeutics, Inc. |
Director |
Common Stock |
33,114 |
$330,478 |
$9.98 |
01 Jul 2024 |
By Crestline Summit Master, SPC - CRESTLINE SUMMIT APEX SP |
| BioAge Labs, Inc. |
Director |
Common Stock |
18,353 |
$330,354 |
$18.00 |
27 Sep 2024 |
CRESTLINE SUMMIT MASTER, SPC - CRESTLINE SUMMIT APEX SP |
| BioAge Labs, Inc. |
Director |
Common Stock |
11,113 |
$200,034 |
$18.00 |
27 Sep 2024 |
Sofinnova Synergy Master Fund LP |
| Rapport Therapeutics, Inc. |
Director |
Common Stock |
18,641 |
$186,037 |
$9.98 |
01 Jul 2024 |
By Sofinnova Synergy Master Fund LP |
| Karuna Therapeutics, Inc. |
Director |
Common Stock |
0 |
$0 |
$330.00 |
18 Mar 2024 |
By Sofinnova Management X, L.P. |
| Karuna Therapeutics, Inc. |
Director |
Common Stock |
0 |
$0 |
$330.00 |
18 Mar 2024 |
By Sofinnova Synergy Master Fund, LP |
| Karuna Therapeutics, Inc. |
Director |
Common Stock |
0 |
$0 |
$330.00 |
18 Mar 2024 |
By Sofinnova Venture Partners X, LP |
| Karuna Therapeutics, Inc. |
Director |
Common Stock |
0 |
$0 |
$330.00 |
18 Mar 2024 |
Direct |
| Karuna Therapeutics, Inc. |
Director |
Option (right to buy) |
0 |
$0 |
$92.30 |
18 Mar 2024 |
Direct |
| Y-mAbs Therapeutics, Inc. |
Director |
Common Stock |
0 |
$0 |
$8.52 |
16 Sep 2025 |
Direct |
| Y-mAbs Therapeutics, Inc. |
Director |
Common Stock |
0 |
$0 |
$8.60 |
16 Sep 2025 |
Indirect |
| Coherus BioSciences, Inc. |
Director |
Stock Option (Right to Buy) |
27,000 |
|
|
07 Jan 2022 |
Direct |
| BioAge Labs, Inc. |
Director |
Stock Option (Right to Buy) |
22,000 |
|
|
05 Jun 2025 |
Direct |
| Bolt Biotherapeutics, Inc. |
Director |
Stock Option (Right to Buy) |
22,000 |
|
|
12 Jun 2024 |
Direct |
| Rapport Therapeutics, Inc. |
Director |
Stock Option (Right to Buy) |
21,850 |
|
|
17 Jun 2025 |
Direct |
| ArriVent Biopharma, Inc. |
Director |
Series B Preferred Stock |
0 |
|
|
30 Jan 2024 |
Sofinnova Venture Partners XI, L.P. |
| BioAge Labs, Inc. |
Director |
Series D Preferred Stock |
0 |
|
|
27 Sep 2024 |
Sofinnova Venture Partners XI, L.P. |
| CinCor Pharma, Inc. |
Director, 10%+ Owner |
Common Stock |
0 |
|
$28.75 |
28 Nov 2022 |
By Sofinnova Synergy Master Fund, LP |
| CinCor Pharma, Inc. |
Director, 10%+ Owner |
Common Stock |
0 |
|
$28.75 |
24 Feb 2023 |
By Sofinnova Venture Partners X, L.P. |
| CinCor Pharma, Inc. |
Director, 10%+ Owner |
Common Stock |
0 |
|
$28.75 |
24 Feb 2023 |
Direct |
| Y-mAbs Therapeutics, Inc. |
Director |
Employee Stock Option (right to buy) |
0 |
|
|
16 Sep 2025 |
Direct |